Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
230 independent labs in 50 countries
36 findings against
1 trial, none about aging, 1 with no results posted
Funders: National Institutes of Health and others
25 of 421 findings with company ties
Human trial5
Humans395
Animals10
What did studies of polypharmacy find?
60
Studies of polypharmacy measured 60 outcomes; the most studied are physical function (8 studies), cognitive function (7) and frailty (6).
Physical function
↓downin humans6↓downin mice2OR 4
8 studies
Polypharmacy is linked with worse physical function in humans.
“Polypharmacy, low muscle mass, and lower educational levels were associated with poorer physical performance.”
Polypharmacy is linked with worse physical function in humans (-1.24 points (95% CI -1.58, -0.90)).
“Estimated CAPP score was 1.24 points lower among participants with polypharmacy vs. no polypharmacy (95% confidence interval [95%CI] -1.58, -0.90; p < 0.001).”
Polypharmacy is linked with worse physical function in humans (cancer) (OR 4.0, 95% CI 1.59-10.06).
“Polypharmacy was associated with the four time the risk of functional impairment in middle-aged (OR 4.0, 95% CI 1.59-10.06) and older individuals (OR 4.4, 95% CI 1.6-11.7).”
The journals of gerontology. Series A, Biological sciences and medical sciences·
Polypharmacy impairs physical function in mice (increasing Drug Burden Index).
“Polypharmacy with increasing DBI and monotherapy with citalopram caused mice to become frailer, less mobile, and impaired their strength and functional activities.”
The journals of gerontology. Series A, Biological sciences and medical sciences·
Cognitive function
↔no changein humans4↓downin humans3
7 studies
Polypharmacy was not clearly linked with cognitive function in humans (African American adults; adjusted for modified Charlson Comorbidity Index) (B = -0.081; β = -0.057; p = 0.257).
“Polypharmacy was not independently associated with cognition after modified CCI adjustment (B = -0.081; β = -0.057; p = 0.257).”
HumansAfrican American adults; adjusted for modified Charlson Comorbidity Index≥5 medications73.6% femalesn = 348
İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi·
Polypharmacy is linked with lower cognitive function in humans (taking ≥8 medications at discharge) (median: 23 vs 32; r = -0.384, P = .016).
“In the 75-89 years age group, polypharmacy defined as taking ≥8 medications at discharge was significantly associated with lower cognitive FIM scores (median: 23 vs 32; r = -0.384, P = .016).”
Polypharmacy increases frailty in mice (increasing Drug Burden Index).
“Polypharmacy with increasing DBI and monotherapy with citalopram caused mice to become frailer, less mobile, and impaired their strength and functional activities.”
Polypharmacy was not clearly linked with mortality in humans (emergency laparotomy).
“There was no significant difference in mortality up to 1 year following surgery between those with or without polypharmacy, nor those with or without significant ACB.”
Polypharmacy is linked with higher mortality in humans (non-valvular atrial fibrillation) (P<0.05).
“all-cause death significantly increased (each, P<0.05). In multivariate analysis, increasing medications was independently associated with increases in these events”
Polypharmacy showed no clear effect on sarcopenia in humans (residents of nursing homes or inpatients).
“There is an association between sarcopenia or risk for sarcopenia and polypharmacy or the number of medications in community-dwelling older adults but not among residents of nursing homes or inpatients.”
İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi·
Polypharmacy is linked with worse activities of daily living in humans (fully adjusted model) (B = 0.14, p = 0.007).
“polypharmacy remained independently associated with poorer functional status in fully adjusted models, showing higher K-ADL scores (B = 0.14, p = 0.007)”
Polypharmacy is linked with lower handgrip strength in humans after adjustment for age, sex, height, arm circumference, and BMI (ptrend<0.001 in men and women).
“Handgrip strength decreased significantly in both men and women (ptrend<0.001 for both) with increasing medication use after adjustment for age, sex, height, arm circumference, and BMI.”
Humansafter adjustment for age, sex, height, arm circumference, and BMImale and females
“Polypharmacy altered the hepatic expression of proteins involved in immunity, and in drug, cholesterol, and amino acid metabolism, accompanied by higher serum drug levels than monotherapies.”
Polypharmacy is linked with a higher risk of mortality in humans (aOR 2.12).
“polypharmacy was independently associated with higher odds of recurrent all-cause ED visits (aOR 2.41), hospitalizations (aOR 2.18), pneumonia-related ED visits (aOR 1.97), pneumonia hospitalizations (aOR 2.63), and mortality (aOR 2.12).”
International Journal of Pharmaceutical Quality Assurance·
Polypharmacy is linked with a higher risk of mortality in humans (fully adjusted models including all higher-risk medication exposures) (HR 1.38; 95% CI 1.26-1.51).
“only polypharmacy remained significantly associated with increased mortality (hazard ratio [HR] 1.38; 95% CI 1.26-1.51).”
Humansfully adjusted models including all higher-risk medication exposuresn = 7,828
Polypharmacy is linked with a higher risk of mortality in humans (dose-response per each additional medication) (HR: 1.05, 95% CI: 1.03-1.06).
“Dose-response meta-analyses showed a monotonic increase in risk with each additional medication for mortality (HR: 1.05, 95% CI: 1.03-1.06, p < .001)”
Humansdose-response per each additional medication
Polypharmacy is associated with mortality in humans after hip fracture surgery (HR 3.65, 95% CI 2.73-4.88; fully adjusted HR 3.12).
“Crude hazard ratios for 5-year mortality were 3.65 (95% CI 2.73-4.88) for patients taking 5-9 drugs and 4.51 (95% CI 3.26-6.24) for those taking ≥ 10 drugs”
Humansafter hip fracture surgery5-9 drugs5 yearsn = 644
Polypharmacy is linked with a higher risk of mortality in humans (Alzheimer's disease confirmed by CSF biomarkers (A+ T+)) (HR 1.06, 95% CI 1.01-1.11).
“In adjusted models, mortality was associated with the number of drugs [hazard ratio (HR) 1.06, 95% confidence interval (CI) 1.01-1.11]”
HumansAlzheimer's disease confirmed by CSF biomarkers (A+ T+)mean follow-up of 7.3 yearsn = 440
Polypharmacy is associated with mortality in humans (critically ill patients receiving mechanical ventilation) (HR 1.17, 95% CI 0.85–1.60).
“patients with polypharmacy at admission were not independently associated with all-cause mortality (hazard ratio [HR]: 1.17, 95% confidence interval [CI]: 0.85–1.60).”
Polypharmacy is associated with mortality in humans (undergoing rehabilitation after fracture or elective orthopedic surgery) (HR 2.23, 95% CI 1.24-4.10, p = 0.007).
“polypharmacy was independently linked to a higher risk of mortality, falls and hospitalizations (HR 2.23, 95% CI 1.24-4.10, p = 0.007).”
Humansundergoing rehabilitation after fracture or elective orthopedic surgeryn = 205
Archives of public health = Archives belges de sante publique·
All 55Fewer
Frailty
↑upin humans51↕mixedin humans2↑upin mice1+63% frail participants had polypharmacyOR 1.432–8.22
54 studies
Polypharmacy is associated with frailty in humans (multivariable logistic regression).
“Multivariable logistic regression revealed that living with family, polypharmacy, malnourishment/risk of malnutrition and IADL dependency were independently associated with frailty.”
Polypharmacy is associated with frailty in humans (hospitalized older adults with multimorbidity in Northwest Ethiopia).
“Frailty was significantly associated with PIM, PPO, female gender, use of polypharmacy, and dependency in activities of daily living (ADL) in multivariable analysis.”
Humanshospitalized older adults with multimorbidity in Northwest Ethiopian = 407
Polypharmacy is associated with frailty in humans (Institutionalized older adults) (62.5 % of frail participants had polypharmacy).
“A high frequency of frailty was detected in older adults aged 80 years and older, of female sex, with greater comorbidity and the presence of polypharmacy.”
Polypharmacy is associated with frailty in humans (Older Vietnamese inpatients; univariate analysis) (Polypharmacy prevalence: 53.6% in robust, 75.3% in prefrail, and 80.0% in frail patients; p=0.005).
“Polypharmacy is highly prevalent among older Vietnamese inpatients and is strongly associated with frailty in univariate analysis”
Polypharmacy is linked with a higher risk of falls in humans (hypertensive older adults) (adjusted OR 2.513, 95% CI 1.339, 4.718).
“Polypharmacy (adjusted OR 2.513, 95% CI 1.339, 4.718) and diuretics (adjusted OR 2.803, 95% CI 1.418, 5.544) were associated with an increased risk of falls.”
International journal of environmental research and public health·
Polypharmacy is linked with a higher risk of falls in humans (OR 1.43, 95% CI 1.01-2.03).
“inpatients with polypharmacy had an increased risk of falls (OR 1.37, 95%CI 1.17-1.56 for the cross-sectional association; OR 1.43, 95% CI 1.01-2.03 for the longitudinal association, respectively)”
Polypharmacy is linked with a higher risk of hospitalization in humans (compared to cardiometabolic medications dominant group) (HR 1.09, 95% CI 1.09-1.10).
Archives of public health = Archives belges de sante publique·
Polypharmacy is linked with a higher risk of hospitalization in humans (non-chronic polypharmacy therapy (≤2 DDDs) vs. not on polypharmacy) (+39% (95% CI 28%-51%)).
“hospitalization [39% (28%-51%) and 61% (49%-75%), respectively]”
Humansnon-chronic polypharmacy therapy (≤2 DDDs) vs. not on polypharmacyn = 5,631
Polypharmacy is linked with a higher risk of hospitalization in humans (aOR 1.32, 95% CI 1.31-1.33).
“In patients who exhibited polypharmacy for more than 180 days, the adjusted odds ratio of adverse outcomes was 1.32 (95% confidence interval [CI], 1.31-1.33) for hospitalization”
“Being female, polypharmacy, the presence of at least one comorbidity, cancer, and chronic renal failure were found to be independent predictors of hospitalization”
Polypharmacy is associated with sarcopenia in humans (adjusted for sex, age, comorbid conditions and physical activity) (OR 2.24, 95% CI 1.33-3.75).
“polypharmacy was consistently associated with a significantly increased likelihood of sarcopenia (odds ratio = 2.24, 95% confidence interval [CI] = 1.33-3.75)”
Humansadjusted for sex, age, comorbid conditions and physical activity
Polypharmacy is associated with physical function in humans (adjusted for age, sex, BMI, and comorbidities (Model 2)) (OR 2.4, 95% CI 1.2-4.8).
“polypharmacy was independently associated with poor SPPB (Odds Ratio (OR)=2.5; 95% Confidence Interval (CI)=1.3-4.7 and OR=2.4; 95% CI=1.2-4.8 for Model 1 and 2, respectively)”
Humansadjusted for age, sex, BMI, and comorbidities (Model 2)n = 392
Polypharmacy is associated with physical function in humans.
“polypharmacy is associated with increased adverse reactions, drug interactions, recurrent hospitalizations, functional impairment, frailty, and mortality.”
Polypharmacy is associated with multimorbidity in humans (Adjusted association in adults attending a rural primary care hospital) (Adjusted OR 2.31, 95% CI 0.92–5.81; p=0.076; not statistically significant).
“Polypharmacy was associated with increased odds of multimorbidity, although the adjusted association was not statistically significant”
HumansAdjusted association in adults attending a rural primary care hospitaln = 304
Polypharmacy is associated with multimorbidity in humans (elderly of an educational program) (P < .05).
“being higher among elderly individuals self-reporting their health as regular or bad/or very bad, having systemic arterial hypertension, diabetes mellitus, dyslipidaemia, hypothyroidism, overweight/obesity, and depression, including polypharmacy (P < .05)”
Polypharmacy is associated with handgrip strength in the low-HGS group (B=-0.064, approximately 6% lower improvement).
“In the low-HGS group, polypharmacy was independently associated with poorer HGS recovery (B=-0.064), corresponding to approximately 6% lower improvement.”
Japanese journal of comprehensive rehabilitation science·
Cognitive function
↑upin humans2↓downin humans2
4 studies
Polypharmacy is associated with cognitive function in humans (unadjusted analysis) (p < 0.05).
“Polypharmacy was associated with better functional and cognitive scores in unadjusted analyses (p < 0.05), although these associations were not independent after adjustment.”
Polypharmacy is associated with cognitive function in humans.
“reductions from moderate or high to lower polypharmacy levels yielded cognitive improvements - particularly in motor function - in both PWH and VS-PWH populations.”
HumansReduction from moderate or high to lower polypharmacy in people with HIV, including virally suppressed people
International journal of environmental research and public health·
Functional status
↓downin humans3↑upin humans1
4 studies
Polypharmacy is associated with functional status in humans (unadjusted analysis) (p < 0.05).
“Polypharmacy was associated with better functional and cognitive scores in unadjusted analyses (p < 0.05), although these associations were not independent after adjustment.”
Polypharmacy is associated with functional status in humans (Polypharmacy and excessive polypharmacy groups).
“Proportion of subjects with a decline in cognitive status, functional status and mobility increased in polypharmacy and excessive polypharmacy group.”
HumansPolypharmacy and excessive polypharmacy groups5–9 or ≥10 medicationsn = 88,878
An observational study found no significant survival differences with hormone therapy among women with stage I breast cancer who were older, had other illnesses or took…An observational study found no significant survival differences with hormone therapy among women with stage I breast cancer who were older, had other illnesses or took multiple medicines.